Form 4 for NRIX Nurix Therapeutics, Inc.
Accepted 2025-09-17 00:00:00 ET · period of report 2025-09-17 · accession 0001226675-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-17 | 2025-09-17 | NRIX | GREGORY JULIA P | Dir | M - OptEx | $1.86 | +10.8K | 10.8K | New | +$20.0K |
| D | 2025-09-17 | 2025-09-17 | NRIX | GREGORY JULIA P | Dir | M - OptEx | $0.00 | -10.8K | 22.6K | -32% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-17 | M | A | 10,750 | $1.86 | 10,750 | D | — | — | |
| 2 | Derivative | Director Stock Option (right to buy) | 2025-09-17 | M | D | 10,750 | $0.00 | 22,583 | D | $1.86 · — to 2029-12-22 | 10,750 Common Stock | (F1) The stock option vested as to 1/48 of the total shares monthly beginning September 12, 2019, and was vested in full on August 12, 2023. |